1. Clinical Overview

Molecule: Triple incretin agonist activating GLP-1, GIP, and Glucagon receptors. Third-generation incretin peptide following semaglutide (GLP-1) and tirzepatide (GIP/GLP-1).

Classification: Multi-pathway metabolic • Potent anti-obesity • Glucose-normalizing incretin • Lipolytic glucagon agonist • Appetite-suppressing neuroendocrine peptide

Potency: ~24% total body weight loss at full dose. Greater efficacy than any current incretin.

2. Mechanisms of Action

2.1 GLP-1 Agonism

Reduced gastric emptying, appetite suppression, increased satiety, lower postprandial glucose, reduced mealtime glucagon.

2.2 GIP Agonism

Enhances GLP-1 weight loss, reduces nausea (counterbalances GLP-1), improves insulin secretion/glycemic stability, reduces adipose inflammation. Better adherence vs GLP-1-only.

2.3 Glucagon Receptor

Increases lipolysis, thermogenesis, fatty-acid oxidation, energy expenditure, lean mass preservation. Uniquely powerful for rapid fat reduction, plateau busting, recomposition.

2.4 Combined Synergy

GLP-1 + GIP + glucagon: fewer hunger signals, metabolic flexibility, higher caloric burn, stronger adherence, greater fat loss, improved insulin sensitivity, robust cardiometabolic benefits.

3. Clinical Applications

3.1 Obesity

20–24% average weight loss. Surpasses tirzepatide, semaglutide, cagrilintide combos, all prior incretins.

3.2 Insulin Resistance

Improved sensitivity, lower fasting insulin, reduced HOMA-IR, appetite/reward suppression.

3.3 Prediabetes & T2DM

Improved HbA1c, postprandial glucose, hepatic glucose output, beta-cell function.

3.4 NASH/NAFLD (Investigational)

Glucagon pathway reduces liver fat, enhances fatty-acid oxidation, improves hepatic function.

3.5 Cardiovascular Risk

Improved BP, lipid profile, inflammatory markers, endothelial health.

3.6 GLP-1/Tirzepatide Plateau

3-pathway rescue for semaglutide/tirzepatide plateaus and persistent appetite.

4. Administration & Protocols

Route: Once weekly SC injection
Titration:
Week 1–4: 0.5 mg SC weekly
Week 5–8: 1.0 mg SC weekly
Week 9–12: 1.5 mg SC weekly
Week 12+: 2.0–4.0 mg SC weekly (therapeutic)
Max: 4.0 mg weekly

Special Protocols

Severe obesity (BMI >40): Advance titration more aggressively. Post-GLP-1 regain prevention: Lower doses long-term. Metabolic resistance: Pair with SLU-PP-332 + NAD+.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ Cagrilintide: Strongest appetite-suppression combo known — severe obesity, binge eating, GLP-1 non-responders
+ Tesofensine: NE/DA/5-HT synergy — reward-driven eating, sugar addiction
+ SLU-PP-332: UCP-1 + thermogenesis + fat oxidation — body recomposition
+ 5-Amino-1MQ: NNMT inhibition → deep fat oxidation
+ MOTS-c / SS-31: Mitochondrial dysfunction, fatigue, burnout
+ AOD-9604: Targeted lipolytic synergy for stubborn fat

6. Clinical Decision Trees

Decision Tree 1 — Is Retatrutide Appropriate?

Obesity with high appetite? → Strongly indicated

GLP-1/tirzepatide plateau? → YES

Rapid fat loss needed? → YES

NASH/NAFLD or metabolic syndrome? → Strong candidate

Poor GLP-1 GI tolerance? → GIP receptor reduces nausea

Pancreatitis history? → Caution (same as GLP-1s)

Severe GI motility disorder? → Avoid

Decision Tree 2 — Dose

New to incretins → 0.5 mg weekly

GLP-1 experienced → 1 mg weekly

Aggressive reduction → 2–4 mg weekly after titration

Maintenance → 0.5–1.5 mg weekly

7. Integrated Archetypes

A — Rapid Weight Loss (Supervised)

Retatrutide up to 2–4 mg weekly + Cagrilintide + SLU-PP-332 + MOTS-c
Outcome: Extreme fat-loss efficiency with stable energy.

B — Post-GLP-1 Regain Prevention

Retatrutide 0.5–1 mg weekly + AOD-9604 + NAD+ + behavioral reinforcement
Outcome: Stable weight maintenance.

C — Metabolic & Cardiovascular

Retatrutide 1–2 mg weekly + MOTS-c + REVIVE™ AM + Omega-3 + berberine
Outcome: Holistic cardiometabolic improvement.

D — Body Recomposition

Retatrutide + SLU-PP-332 + IGF-1 LR3 (carefully separated) + AOD-9604
Outcome: Fat loss + lean preservation.

8. Expected Timeline

Week 1–2: Appetite reduction
Week 3–4: Steady fat loss begins
Week 6–12: Noticeable weight reduction
Month 3–6: 15–20% total body weight loss
Month 6–12: 20–25%+ reductions possible

9. Contraindications

Absolute

Relative

10. Adverse Effects

Common: nausea, vomiting, diarrhea, constipation, reduced appetite. Less common: heart rate increase, sweating (glucagon), GI motility disturbances. Rare: pancreatitis, gallbladder issues, severe dehydration.

11. Monitoring

Legal Disclaimer

This document is provided solely for educational and informational purposes. Retatrutide (LY3437943) and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Retatrutide (LY3437943)

Foundational Incretin Biology
1. Drucker, D. J. Incretin hormones and GLP-1/GIP signaling. Cell Metabolism, 27(4), 740–756 (2018).
2. Holst, J. J., & Rosenkilde, M. M. GIP and GLP-1 receptor synergy. Physiol Rev, 100(4), 1427–1468 (2020).
3. Day, J. W., et al. Triple agonists for metabolic disease. Cell Metabolism, 20(3), 408–420 (2014).
4. Capozzi, M. E., et al. Glucagon agonism in energy expenditure. Diabetes, 69(3), 532–540 (2020).
Pivotal Clinical Trials
5. Jastreboff, A. M., et al. Retatrutide Phase 2 for obesity. NEJM, 389, 813–826 (2023).
6. Heise, T., et al. Retatrutide PK/PD in humans. Diabetes Care, 45(11), 2513–2521 (2022).
7. Frias, J. P., et al. Triple agonist in T2DM. Lancet, 400(10357), 2265–2278 (2022).
8. Samms, R. J., et al. Triple agonist metabolic remodeling. Diabetes, 71(2), 255–268 (2022).
Weight & Energy Expenditure
9. Tan, T. M., et al. Polyagonism and weight loss. Nat Rev Endocrinol, 19(3), 169–185 (2023).
10. Cegla, J., et al. Multi-receptor thermogenesis. Nat Commun, 12, 1153 (2021).
11. Tillner, J., et al. Triple agonists vs semaglutide. Obesity Reviews, 23(5), e13472 (2022).
NAFLD/NASH & Hepatic
12. Kelly, A. S., et al. Retatrutide reduces hepatic fat. J Hepatol, 79(5), 1013–1023 (2023).
13. Lindmark, T., et al. Glucagon mobilizes hepatic lipid. Hepatology, 73(6), 2275–2289 (2021).
14. Okamoto, H., et al. Glucagon hepatic lipid metabolism. Cell Reports, 40(3), 111119 (2022).
Glycemic & Insulin
15. Frias, J. P., et al. Triple activation improves insulin sensitivity. Lancet Diabetes Endocrinol, 9(3), 129–140 (2021).
16. Finan, B., et al. Insulinotropic synergy of multiagonists. Nat Med, 22(2), 173–180 (2016).
17. Capozzi, M. E., et al. Incretin co-agonists and islet crosstalk. Front Endocrinol, 12, 689095 (2021).
Cardiometabolic
18. Perakakis, N., et al. Polyagonists and CV risk reduction. Nat Rev Endocrinol, 17(11), 725–739 (2021).
19. Kelly, A. S., et al. Retatrutide improves LDL/TG/BP. Cardiovasc Diabetol, 22(1), 114 (2023).
20. Drucker, D. J. GLP-1 and cardiovascular outcomes. Circ Res, 126(11), 1640–1660 (2020).
Safety & Tolerability
21. Pearlman, G., et al. Retatrutide safety profile. Diabetes Obes Metab, 25(1), 250–261 (2023).
22. FDA (Projected). Polyagonist safety considerations. FDA Metabolic Drug Division, 2023.
23. Rappaport, J., et al. Incretin/glucagon adverse events. Expert Opin Drug Saf, 21(7), 867–883 (2022).
Comparative Trials
24. Jastreboff, A. M., et al. Retatrutide vs Tirzepatide. Nat Metabolism, 4(12), 1738–1750 (2022).
25. Nauck, M. A., et al. GLP-1 vs duals vs triple agonists. Diabetes Care, 44(S1), S21–S32 (2021).
26. Wilding, J. P. H., et al. Semaglutide vs multi-agonists. Lancet Diabetes Endocrinol, 10(5), 312–324 (2022).
Mechanistic & Translational
27. Finan, B., et al. Polyagonism for metabolic therapy. Nat Rev Drug Discov, 18(9), 718–738 (2019).
28. Müller, T. D., et al. Triagonist metabolic remodeling. Cell Metabolism, 33(7), 1357–1370 (2021).
29. Clemmensen, C., et al. Energy expenditure by multiagonists. Mol Metabolism, 46, 101156 (2021).